Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294125 · ClinicalTrials.gov registry record · Phase 1
Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00294125 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 59 participants.
The verdict
NCT00294125, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to treat arthritis. The purpose of this study is to test the effectiveness of flavocoxid, a plant-derived compound, for the treatment of knee osteoarthritis (OA) in adults. Study hypotheses: 1) Flavocoxid has an acceptable safety and tolerability profile as determined by the Generally Regarded as Safe (GRAS) profile in patients with OA compared to identical placebo. 2) Flavocoxid will be more effective as a therapy for OA compared to identical placebo.
Interventions
- DRUG Placebo
- DRUG Flavocoxid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294125
The ClinicalTrials.gov registry entry for NCT00294125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00294125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294125 about?
NCT00294125 is a clinical study titled "Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis". Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to treat arthritis. The purpose of this study is to test the effectiveness of flavocoxid, a plant-derived compound, for the treatment of knee osteoarthritis (OA) in adults. Study hypotheses: 1) Flavocoxid has an acceptable safety...
What is the current status of trial NCT00294125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2006-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00294125?
The interventions under investigation include: Placebo (DRUG), Flavocoxid (DRUG).
Who is sponsoring clinical trial NCT00294125?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.